PharmaNutra SpA (PHN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Corentin Marty from TP ICAP MIDCAP maintained a Buy rating on the stock and has a €74.00 price target.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Corentin Marty has given his Buy rating due to a combination of factors that highlight PharmaNutra SpA’s potential for growth and stability. The company’s Q1 2025 results showed a significant revenue increase of 11.2% year-over-year, driven largely by strong international sales, which grew by 18.2%. This international expansion is a key growth driver, with PharmaNutra now operating in 92 countries, and further growth is anticipated with the upcoming contribution from PHN USA in the second half of the year.
Despite a slight decline in EBITDA due to investments in new business units, the company’s net cash position improved significantly, indicating strong financial health. Management’s confidence in maintaining growth throughout 2025, despite macroeconomic uncertainties, aligns with the analyst’s expectations. Although there is caution regarding profitability and potential margin pressures, the overall outlook remains positive, leading to the maintenance of a target price of €74 and the reiteration of a Buy rating.